Further information about third Pfizer dose - Follow Up

Additional information: Third Primary Dose
Yesterday we announced a third dose of the Pfizer vaccine would be available for people who are severely immuncompromised. We anticipate this option will only be suitable for a very small group of the population. 

continued...

The main things to note are:
 
·         A third primary dose vaccine cannot be prescribed or administered to anyone who does not meet the criteria set out in the Policy Statement. 
·         The third primary dose must be administered at least 8 weeks following the second dose.  
·         Patients must show a script from a medical practitioner and a written consent form (co-signed by the medical practitioner) to receive a third primary dose.
·         The third primary dose can be administered at all vaccination clinics.  
·         The standard two-dose course of vaccine should be offered to any eligible unvaccinated household contacts aged 12 and over, of severely immunocompromised individuals. 
·         The Ministry of Health has published the requirements to be eligible for a third dose (see , which can be viewed online (see Policy Statement)   
·         Information for clinicians is available in the Immunisation Handbook and IMAC website.

• The Unite Against COVID website will be updated with public messaging by tomorrow.
• Further information is available on the Health Pathways website.
• An updated consent form will be uploaded to the Ministry website this afternoon.
• Further information regarding funding for consultations and prescriptions will be provided later this week.

 
 
The attached documents will help you understand the eligibility criteria for this third primary dose of Pfizer. This information will be loaded to the Ministry of Health’s website this afternoon.
 
Please note the COVID-19 Vaccination Immunisation Operating Guidelines will shortly be updated to include this change.

Click here to read the policy statement and clinical guidance
Click here to read the third primary dose consumer access journey

---